Skip to main content

Diabetes (ADA) 'Under Review': What Each Status Means and When to Expect a Decision

If your Diabetes submission shows Under Review, here is what the ADA Editor-in-Chief and Associate Editor are doing during each stage and when to follow up.

Editorial processThe Manusights editorial team researches and maintains these guides using source review, field-specific analysis, and our documented editorial process.How we work

While you wait

Waiting on a decision? Get your next move ready.

The wait is out of your hands; the next move isn't. Scan your next manuscript free, or run this paper through the scan to see what reviewers typically push back on, so the revision response is ready when the decision lands.

Check my next manuscriptPrivate API processing. Your manuscript is not used to train models.What the status means

Last reviewed: 2026-10-10. Quick answer: If your Diabetes submission shows "Under Review," elapsed time is the most reliable signal.

Diabetes has a 2025 Journal Impact Factor of 9.3 in the 2026 JCR release, and lists an acceptance rate of 12.39 percent on the journal's own About page, and ADA reports that only those manuscripts that meet a priority score, as determined by the Editor, above the 50th percentile will be reviewed (per Diabetes instructions for authors).

The Editor-in-Chief assesses each submission to determine whether the content and subject of the manuscript is appropriate for the journal.

Each manuscript that meets the priority score above the 50th percentile is assigned to an Associate Editor who is versed in the subject area of the manuscript. Based on the reviews of 3 peer reviewers, the Associate Editor will recommend a decision to accept the manuscript for publication, reject the manuscript, or suggest that the authors revise and resubmit the manuscript.

For a second opinion before reviewers see your manuscript, run a Diabetes submission readiness check.

Submission portal and editorial contact: Diabetes uses ScholarOne Manuscripts at ScholarOne submission portal. Editorial questions should reference the manuscript ID; DiabetesJournal@diabetes.org is the peer-review office address listed in the Diabetes instructions for authors. The Diabetes instructions for authors and the ADA Journal Policies portal cover the editorial workflow and status-check guidance.

For broader status-tracking guidance across diabetes publishers, the Cell Press author status portal gives useful baseline patterns for reading status fields across editorial portals.

How does ADA handle a Diabetes submission?

Diabetes operates the ADA Editor-in-Chief + Associate Editor priority-score model. The Editor-in-Chief assesses each submission to determine whether the content and subject of the manuscript is appropriate for the journal. Due to an increasing number of submissions and limited editorial space, only those manuscripts that meet a priority score above the 50th percentile will be reviewed.

Diabetes editorial culture is decisive: the EIC priority-score gate filters out manuscripts below the 50th percentile, and only those above pass to Associate Editor + 3-reviewer review. Papers that pass the Diabetes priority-score threshold have cleared the steepest filter in ADA basic-translational diabetes publishing.

What is Diabetes's review pipeline?

The stage durations below are unofficial estimates; the journal's About page gives only an average time to first decision of 14 days.

Status
What is happening
Unofficial estimate
Submitted
Administrative processing at Diabetes editorial office
Day 0 to 3
EIC Priority Score Assessment
EIC determining priority score threshold
Days 3 to 14
With Associate Editor
Associate editor versed in subject area assigned
Days 14 to 21
Under Review
3 external peer reviewers invited or actively reviewing
Days 21 to 70
Required Reviews Complete
Associate Editor synthesizing 3 reviews
7 to 14 days
Decision Pending
EIC reviewing AE recommendation
7 to 14 days
Decision Sent
Reject, R&R, or accept
Check email

What happens at the EIC priority-score desk screen?

Before the paper reaches Associate Editor assignment, the Diabetes Editor-in-Chief assesses each submission to determine the priority score. Manuscripts that do not reach a priority score above the 50th percentile are not reviewed, and the pages checked give no count of such returns. A return at this stage may mean the EIC concluded that the work would fit better at a sister ADA journal (Diabetes Care for clinical diabetes research, Clinical Diabetes for primary-care diabetes, Diabetes Spectrum for diabetes education) or that the basic-translational diabetes priority bar is not met.

What happens at each stage after submission?

  • Day 0 to 3, file check: The Diabetes editorial office confirms files are complete: the manuscript, figure files and supplementary information uploaded separately, the signed manuscript submission form, the cover letter, conflict-of-interest declarations, ethics statements, and the data and resource availability statement.
  • Days 3 to 14, priority-score gate: The EIC assesses each submission to determine whether the content and subject of the manuscript is appropriate for the journal, applying the priority-score gate. Due to an increasing number of submissions and limited editorial space, only those manuscripts that meet a priority score above the 50th percentile will be reviewed.
  • Days 14 to 21, Associate Editor assignment: Papers that meet the priority score above the 50th percentile are assigned to an Associate Editor who is versed in the subject area of the manuscript. The Associate Editor invites 3 expert peer reviewers.
  • Days 21 to 35, reviewer recruitment: Diabetes Associate Editors invite expert peer reviewers, and the decision recommendation rests on the reviews of three; the unofficial estimate for reviewer recruitment is 7 to 14 days. The recruitment window can take longer because reviewers with topic-matched basic-translational diabetes subspecialty expertise are scarce.
  • Days 21 to 70, peer review: Once reviewers agree to review, the unofficial estimate for a Diabetes peer-review cycle is 3 to 6 weeks per reviewer. Based on the reviews of 3 peer reviewers, the Associate Editor will recommend a decision.
  • After day 70, synthesis and decision: After 3 reports return, the Associate Editor synthesizes them and recommends a decision to the EIC. The EIC reviews and issues the final decision.

When to worry

  • Return within 1 to 14 days: EIC priority-score return for below-50th-percentile work.
  • Still Under Review after 3 weeks: Strong signal. Paper met the priority-score threshold and is in active review.
  • Still Under Review after 10 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the ScholarOne portal is appropriate.
  • Status changes to "Decision Pending": Reports are in; expect a decision within 1 to 2 weeks.

"My paper has been Under Review for 6 weeks. Is that bad?"

This is the most common anxiety we hear from Diabetes authors during the active editorial window. The honest answer: no, 6 weeks at Under Review sits in the middle of the unofficial 6 to 10 week peer-review estimate for papers passing priority-score threshold. Reports may already be in editorial synthesis with the Associate Editor preparing the recommendation.

Most reviewer-driven delays come from recruitment timing for the 3-reviewer model (which is harder than 2-reviewer norms) rather than slow reviews. If the portal still says Under Review at the 9-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the Associate Editor granted it. Reviewers are asked to tell the journal if they will need an extension (ADA Information for Reviewers).

At 6 to 9 weeks, a status inquiry usually helps only if a concrete manuscript-record issue changed: IRB language needs correction, animal-care documentation changed, a related article appeared, a data-availability link broke, or a corresponding-author record is wrong. If none of those changed, wait until 10 weeks and then send one concise ScholarOne message with the manuscript ID, title, submission date, current status, and a request for confirmation that reviewer reports remain pending.

What to do while waiting

  • Do not email the editorial office during the first 6 weeks unless an urgent ethics issue surfaces.
  • Do not submit the paper anywhere else while it is Under Review at Diabetes. ADA has explicit prohibitions on dual submission.
  • Prepare a point-by-point response template for likely reviewer concerns: basic-translational diabetes significance, methodological rigor, reproducibility.
  • If you have related work submitted elsewhere or recently published, prepare disclosure language for when revisions are requested.
  • Read recent Diabetes papers in your subfield to calibrate the current editorial bar.

Status inquiry checklist

Use this checklist before contacting Diabetes about an Under Review manuscript:

  • Confirm the paper has been Under Review for at least 10 weeks or that a material ethics, authorship, IRB, animal-care, data-accession, or related-publication issue changed.
  • Include the manuscript ID, exact title, corresponding author name, submission date, and current ScholarOne status.
  • Ask for a factual status confirmation, not an acceleration request.
  • Keep the message to one short paragraph and do not reargue priority score.
  • Do not send repeated inquiries while the Associate Editor is waiting for reviewer reports.

If Diabetes rejects, what cascade makes sense?

If your Diabetes paper is rejected after review, the natural cascade depends on what the reviewers and Associate Editor cited:

Diabetes Care is the natural ADA cascade for clinical diabetes research where the basic-translational priority bar of Diabetes is not met. Diabetes Care uses ScholarOne at ScholarOne submission portal; editorial contact diabetescare@diabetesjournals.org.

Clinical Diabetes is the ADA cascade for primary-care diabetes practice papers.

Diabetes Spectrum is the ADA cascade for diabetes education and management papers.

Journal of Diabetes (Wiley) is the external cascade for general diabetes research. Wiley uses Editorial Manager at Editorial Manager submission portal; editorial contact jdiabetes@wiley.com.

Diabetologia is the external EASD cascade for European diabetes research.

Cell Metabolism is the external Cell Press cascade for top-tier metabolism-focused diabetes research. Cell Press uses Editorial Manager at Editorial Manager submission portal; editorial contact cellmetabolism@cell.com.

Readiness check

While you wait, scan your next manuscript.

The scan takes about 2 to 3 minutes. Use the result to decide whether to revise before the decision comes back.

Check my next manuscriptPrivate API processing. Your manuscript is not used to train models.Open status guide

How does Diabetes compare to nearby alternatives?

Feature
Diabetes
Diabetes Care
Diabetologia
Cell Metabolism
Desk-rejection rate
Not published (only manuscripts above the 50th-percentile priority score are reviewed)
Not published
Not published
Not published
Desk-decision speed
14 days (journal-reported average time to first decision)
18 days (journal-reported average time to first decision)
Not published
7 days (Cell Press median to first editorial decision)
Total review time (post-screen)
Not published
Not published
Not published
Not published
Reviewer count
3
2 to 3 diabetes experts
2 to 3
2 to 3
Peer-review model
Single-blind + priority-score gate
Single-blind
Single-blind
Cell Press transparent (optional)
Editorial bar
Top ADA basic-translational diabetes priority
Top ADA clinical diabetes
EASD European diabetes research
Top-tier metabolism + broad biology

Publisher-reported acceptance figures link to their source. Elsevier catalog figures were checked on October 21, 2026; the catalog does not specify the reporting period or submission denominator.

Submit If

If your Diabetes paper is Under Review past 3 weeks, you have met the priority-score threshold above the 50th percentile. Use the waiting window to prepare a thorough revision response template anticipating 3-reviewer feedback.

Diabetes submission readiness check takes about 5 minutes.

Think Twice If

Diabetes Associate Editors retain discretion to reject after partial review if reviewer reports surface methodological or basic-translational-diabetes-significance concerns the priority-score assessment did not catch. The journal's listed acceptance rate of 12.39 percent means many post-priority-score papers still receive a substantial-revision or reject decision.

  • Think twice if the abstract explains a metabolic phenotype but not the broader basic-translational diabetes priority.
  • Think twice if the first figure, animal-methods section, qPCR table, or data-availability statement cannot stand up to ARRIVE, MIQE, IRB, or reproducibility scrutiny.

For a pre-upload diagnostic of basic-translational diabetes priority framing and methodological rigor, run a Diabetes pre-submission diagnostic before reviewer reports surface those concerns.

Last verified: Diabetes instructions for authors at Diabetesjournals author instructions and ADA editorial documentation.

What do Diabetes reviewers evaluate?

ADA asks reviewers to rate several things specifically (see the ADA Information for Reviewers). The table below maps them to actionable preparation.

Reviewer focus area
What ADA asks reviewers to do
How to prepare for it
Study design, quality of research, and novel findings
Reviewers give a percentage ranking based on study design, quality of research, and novel findings.
Frame the introduction around the broader-diabetes mechanism the findings illuminate. The 50th-percentile priority-score gate selects for papers with clear diabetes priority. Include detailed methods documentation; state the animal-care guidelines followed for animal work, the Declaration of Helsinki principles for human work, and trial registration where it applies.
Statistical analyses and conclusions
Reviewers give a numbered rating for statistical analyses and conclusions.
Describe the statistical analyses in full and keep the conclusions inside the design and the model system.
Originality, clarity, and interest to the readership
Reviewers give a numbered rating for originality, clarity, and interest to the readership.
Say what is new in the first paragraph. Diabetes requires data and resource availability statements; deposit raw data, original images, and code in public repositories.
Strengths, weaknesses, and value
Reviewers write a brief comment on the strengths, weaknesses, and value of the work; ADA recommends 3 to 5 strengths and 3 to 5 weaknesses.
Anticipate that three reviewers can raise different points; prepare for broader methodological scrutiny.

Common patterns we see that miss the Diabetes bar

In our pre-submission work with Diabetes-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the priority-score gate.

Below-50th-percentile priority framing flagged at EIC priority-score assessment. When the introduction frames the work too narrowly without broader basic-translational diabetes priority, EIC priority-score return below the 50th percentile is common. The strongest manuscripts frame the introduction around a broader-diabetes mechanism the findings address.

Check whether your Diabetes priority framing clears the EIC gate →

Reproducibility framing gaps surface as 3-reviewer concerns. When data are not deposited in public repositories or methods documentation is thin, reviewers consistently flag reproducibility concerns. The 3-reviewer model means more diverse feedback than 2-reviewer norms; the strongest revisions deposit raw data and code alongside submission.

Check your methods, data, ARRIVE, and MIQE package →

ADA family cascade offers from Associate Editor. When the Associate Editor concludes the work is rigorous but the basic-translational priority bar of Diabetes is not met, transfer offers to Diabetes Care (clinical diabetes research), Clinical Diabetes (primary-care), or Diabetes Spectrum (education) are possible; the ADA Information for Reviewers notes that reviewers may be asked to permit the transfer of their reviews to other journals.

Check if your manuscript fits Diabetes, Diabetes Care, Clinical Diabetes, or Diabetes Spectrum →

We have reviewed 50+ manuscripts targeting Diabetes, Diabetes Care, Diabetologia, Cell Metabolism, and broader metabolic-disease journals. Full Manusights reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

In our pre-submission review work across diabetes and metabolism targets, we see five recurring preventable risks before peer review: weak priority framing, incomplete animal-care or IRB context, missing MIQE-style qPCR details, insufficient data traceability, and a cascade plan that confuses basic-translational diabetes with clinical diabetes.

Source limitation: official guidance explains Diabetes's priority-score gate, Associate Editor assignment, reviewer model, and ADA policies, but it cannot diagnose whether your abstract, first figure, methods section, qPCR table, and data package satisfy the EIC, Associate Editor, and three assigned reviewers.

Methodology note

This page was created from ADA's public Diabetes instructions for authors at Diabetesjournals author instructions, ADA Journal Policies documentation (EIC priority-score gate above 50th percentile, Associate Editor versed in subject area assignment, 3-reviewer model, EIC final decision), and Manusights pre-submission review experience with Diabetes-targeted manuscripts.

For the ADA diabetes landscape beyond Diabetes flagship, see Diabetes Care (clinical diabetes), Clinical Diabetes (primary-care), Diabetes Spectrum (education), and external diabetes alternatives (Journal of Diabetes, Diabetologia, Cell Metabolism). The choice across these titles depends on whether the central contribution is top ADA basic-translational diabetes (Diabetes), top ADA clinical diabetes (Diabetes Care), primary-care diabetes (Clinical Diabetes), diabetes education (Diabetes Spectrum), general diabetes research (Journal of Diabetes), EASD European diabetes (Diabetologia), or top-tier metabolism (Cell Metabolism).

At Diabetes the Associate Editor chooses expert reviewers, and the decision recommendation rests on the reviews of three peer reviewers. Editors screen and triage manuscripts before any external reviewer sees them via the priority-score gate, and preparing a response template that anticipates 3-reviewer feedback accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Diabetes basic-translational-diabetes-priority bar before submission, our Diabetes pre-submission diagnostic flags the framing and methodological weaknesses most likely to surface in the priority-score assessment and reviewer reports.

Frequently asked questions

Your manuscript has cleared Diabetes ScholarOne admin checks and is being evaluated. The Editor-in-Chief assesses each submission to determine whether the content and subject of the manuscript is appropriate for the journal. Due to an increasing number of submissions and limited editorial space, only those manuscripts that meet a priority score, as determined by the Editor, above the 50th percentile will be reviewed.

Diabetes operates the ADA priority-score model: each manuscript that meets the priority score above the 50th percentile is assigned to an Associate Editor who is versed in the subject area of the manuscript. Based on the reviews of 3 peer reviewers, the Associate Editor will recommend a decision. An unofficial estimate puts the first decision at 6 to 10 weeks for papers that pass the priority-score threshold; the journal's About page gives an average time to first decision of 14 days.

Wait at least 6 weeks before inquiring. Contact via the Diabetes ScholarOne portal at the official submission portal referencing your manuscript ID; DiabetesJournal@diabetes.org is the peer-review office address listed in the instructions for authors.

No. On the unofficial 6 to 10 week first-decision estimate for papers passing priority-score threshold, 6 weeks is in the middle of the active review range. Reports may already be in editorial synthesis.

Your paper met the priority score above the 50th percentile, was assigned to an Associate Editor versed in the subject area, and 3 peer reviewers have been invited. Diabetes operates single-blind peer review by default.

Yes. On an unofficial estimate, the 6 to 10 week peer-review window plus revision rounds means total submission-to-acceptance commonly runs 4 to 8 months for successful papers.

Past 10 weeks is the right moment for a polite inquiry. Past 14 weeks may mean a reviewer dropped out and the Associate Editor needs a replacement. Silence in the first 6 weeks is normal at Diabetes given the multi-stage ADA editorial workflow.

References

Sources

  1. Diabetes Instructions for Authors
  2. ADA Journal Policies
  3. ADA Information for Reviewers
  4. Diabetes Care Instructions for Authors
  5. ADA Journals Resources

Free guide

Waiting is not the same as being ignored, and there is a way to tell.

Reviewers usually get ten days. When it has been months, an appeal and a complaint are different instruments with different addresses, and only one of them fits a delay. This is which to use, and the wording that gets an answer.

The guide, plus the weekly brief on getting published. One email on Mondays and a product note at most once a month, unsubscribe in one click.

Final step

Done interpreting the status? Put the wait to work.

The decision will arrive on the journal's clock. What you control is what's next: scan your next manuscript free, or run this paper through the scan so the likely reviewer pushback is mapped before the revision request lands.

Free scan, no card needed.

Check my next manuscript

Private API processing. Your manuscript is not used to train models.

Re-read the status guide

Put the guidance to work

Turn a decision into a clear next step.

Use the practical response workflow when a manuscript needs revision, or the process guide when you need to understand what the editorial status means.

Internal navigation

Where to go next